Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs

被引：49

作者：

Ancizu, Saioa ^{[2
]}

Moreno, Elsa ^{[2
]}

Torres, Enrique ^{[2
]}

Burguete, Asuncion ^{[2
]}

Perez-Silanes, Silvia ^{[2
]}

Benitez, Diego ^{[1
]}

Villar, Raquel ^{[2
]}

Solano, Beatriz ^{[2
]}

Marin, Adoracion ^{[2
]}

Aldana, Ignacio ^{[2
]}

Cerecetto, Hugo ^{[1
]}

Gonzalez, Mercedes ^{[1
]}

Monge, Antonio ^{[2
]}

机构：

[1] Univ Republica, Lab Quim Organ, Fac Ciencias, Fac Quim, Montevideo 11400, Uruguay

[2] Univ Navarra, Unidad Invest & Desarrollo Medicamentos, CIFA, Pamplona 31008, Spain

来源：

MOLECULES | 2009年 / 14卷 / 06期

关键词：

quinoxaline; neglected diseases; Mycobacterium tuberculosis; Trypanosoma cruzi; MYCOBACTERIUM-TUBERCULOSIS; 1,4-DI-N-OXIDE DERIVATIVES; ANTIMYCOBACTERIAL ACTIVITY; GROWTH-INHIBITORS; TRYPANOSOMA-CRUZI; QUINOXALINE-2-CARBONITRILE; 1,4-DIOXIDE; AGENTS;

D O I：

10.3390/molecules14062256

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Neglected diseases represent a major health problem. It is estimated that one third of the world population is infected with tuberculosis (TB). Besides TB, Chagas disease, affects approximately 20 million people. Quinoxalines display great activities against TB and Chagas. Forty new quinoxaline 1,4-di-N-oxide derivatives have been prepared and tested against M. tuberculosis and T. cruzi. Carboxylic acid quinoxaline 1,4-di-N-oxides (CAQDOs) 5 and 17 showed MIC values on the same order as the reference antituberculosis drug, rifampicin. Meanwhile, CAQDOs 12 and 22 presented IC50 values in the same order as the anti-chagasic drug, nifurtimox.

引用

页码：2256 / 2272

页数：17

共 26 条

[1] Quinoxaline NN′-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi.: Structure-activity YP relationships
Aguirre, G
Cerecetto, H
Di Maio, R
González, M
Alfaro, MEM
Jaso, A
Zarranz, B
Ortega, MA
Aldana, I
Monge-Vega, A
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (14) : 3835 - 3839
[2] New potent imidazoisoquinolinone derivatives as anti-Trypanosoma cruzi agents: Biological evaluation and structure-activity relationships
Bollini, Mariela
Jose Casal, Juan
Alvarez, Diego E.
Boiani, Lucia
Gonzalez, Mercedes
Cerecetto, Hugo
Maria Bruno, Ana
[J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (04) : 1437 - 1444
[3] Cerecetto Hugo, 2002, Current Topics in Medicinal Chemistry, V2, P1187, DOI 10.2174/1568026023393066
[4] Cerecetto H, 2007, TOP HETEROCYCL CHEM, V10, P265, DOI 10.1007/7081_2007_064
[5] Anti-T. cruzi Agents: Our Experience in the Evaluation of More than Five Hundred Compounds
Cerecetto, Hugo
Gonzalez, Mercedes
[J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2008, 8 (13) : 1355 - 1383
[6] CHEESEMAN GWH, 1979, CONDENSED PYRAZINES, P35
[7] Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium
Collins, LA
Franzblau, SG
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) : 1004 - 1009
[8] SYNTHESIS OF NEW AMIDE-LINKED N-HYDROXYUREA 5-LIPOXYGENASE INHIBITORS BY AN INTRAMOLECULAR OXYGEN TO NITROGEN ACYL TRANSFER
DELLARIA, JF
SALLIN, KJ
RODRIQUES, K
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1993, 3 (02) : 305 - 308
[9] González M, 2007, TOP HETEROCYCL CHEM, V11, P179, DOI 10.1007/7081_2007_066
[10] Synthesis of new quinoxaline-2-carboxylate 1,4-dioxide derivatives as anti-Mycobacterium tuberculosis agents
Jaso, A
Zarranz, B
Aldana, I
Monge, A
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (06) : 2019 - 2025

← 1 2 3 →